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Abstract
Gemcitabine is widely used as first-line chemotherapeutic drug in the treatment of pancreatic cancer. Our previous ex-
perimental chemotherapy studies have shown that treatment of human pancreatic carcinoma cells with 5-fluorouracil
(5-FU) alters the cellular transporter expression profile and that modulation of the expression ofmultidrug resistance pro-
tein 5 (MRP5; ABCC5) influences the chemoresistance of these tumor cells. Here, we studied the influence of acute and
chronic gemcitabine treatment on theexpressionof relevant uptake andexport transporters in pancreatic carcinomacells
by reverse transcription–polymerase chain reaction (RT-PCR), quantitative RT-PCR, and immunoblot analyses. The spe-
cific role of MRP5 in cellular gemcitabine sensitivity was studied by cytotoxicity assays usingMRP5-overexpressing and
MRP5-silenced cells. Exposure to gemcitabine (12 nM for 3 days) did not alter themessenger RNA (mRNA) expression of
MRP1,MRP3,MRP5, and equilibrative nucleoside transporter 1 (ENT1), whereas high dosages of the drug (20 μM for
1 hour) elicited up-regulation of these transporters in most cell lines studied. In cells with acquired gemcitabine re-
sistance (up to 160 nM gemcitabine), the mRNA or protein expression of the gemcitabine transporters MRP5 and
ENT1 was upregulated in several cell lines. Combined treatment with 5-FU and gemcitabine caused a 5- to 40-fold
increase inMRP5 andENT1 expressions. Cytotoxicity assays using eitherMRP5-overexpressing (HEKandPANC-1) or
MRP5-silenced (PANC1/shMRP5) cells indicated that MRP5 contributes to gemcitabine resistance. Thus, our novel
data not only on drug-induced alterations of transporter expression relevant for gemcitabine uptake and export but also
on the link between gemcitabine sensitivity and MRP5 expression may lead to improved strategies of future chemo-
therapy regimens using gemcitabine in pancreatic carcinoma patients.
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Introduction
Pancreatic cancer is the fourth most common cause of cancer-related
death in the western world, with an estimated 35,000 deaths in 2009
in the United States [1]. Less than 20% of pancreatic cancer patients
are diagnosed with resectable and potentially curable disease, whereas
most patients have advanced disease at the time of diagnosis and
hence a dismal prognosis [2]. Median survival of patients with ad-
vanced disease ranges around 6 months despite chemotherapy, mostly
because of an almost complete chemoresistance.
Gemcitabine has been the standard systemic therapy for palliative
treatment of pancreatic cancer for the last decade, although 1-year sur-
vival rates ranging around 18% remain unsatisfactory [3–5]. Despite
the value of gemcitabine in improving clinical benefit, median survival,
and 1-year survival, patients diagnosed with pancreatic carcinoma are
still confronted with poor prognosis amounting to less than 5% sur-
vival beyond 5 years [2,3]. Treatment of pancreatic cancer patients
with gemcitabine alone or in combination with other cytotoxic drugs
is not curative, and the acquisition of resistance during chemotherapy
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may further limit the therapeutic success. Such resistance of human
cells to the cytotoxic action of chemotherapeutic drugs can be the re-
sult of various mechanisms and cellular targets including microRNA,
all of which have been identified to influence, as single factors or in
combination, resistance to gemcitabine [6–12].
The chemotherapeutic effectiveness of gemcitabine requires not
only efficient uptake of the drug into target cells and intracellular
activation to its active triphosphatemetabolite before incorporation into
DNA and RNA but also sufficient drug concentration and time before
removal from intracellular compartments by export transporters. Cel-
lular uptake of nucleosides such as the cytidine analog gemcitabine
(2′,2′-difluorodeoxycytidine) across plasma membranes occurs pri-
marily through specialized equilibrative or concentrative nucleoside
transporters (ENTs or CNTs) [13]. Gemcitabine is taken up into cells
with high affinity (Km = 18 μM) by CNT1 (gene symbol: SLC28A1)
[14], by CNT3 (SLC28A3) [15], and also by ENT1 (SLC29A1) and
ENT2 (SLC29A2) albeit with less affinity (ENT1, Km = 160 μM;
ENT2, Km = 740 μM) [16]. In pancreatic tumor cells, ENT1 is ex-
pressed at high levels, whereas members of the CNT family are present
only at negligible or at a low functional level [17]. Interestingly, both
ENT1 and CNT1 expressions have previously been linked to gemcita-
bine resistance or sensitivity of pancreatic cancer cells [14,17–19]. Pre-
liminary data indicated that export of gemcitabine or its phosphorylated
metabolites into the extracellular space is mediated by multidrug resis-
tance protein 5 (MRP5; gene symbol: ABCC5), a member of the ATP
binding cassette (ABC) transporter family [20]. Among other ABC
transporters,MRP3 (ABCC3),MRP4 (ABCC4), andMRP5 (ABCC5)
are expressed in normal or diseased human pancreas [21–26] and have
been demonstrated to confer resistance against chemotherapeutic drugs
such as etoposide, 5-fluorouracil (5-FU), and gemcitabine [26–29].
Most importantly, recent studies showed that expression levels of the
nucleoside uptake transporters ENT1 and CNT3 (SLC28A3) are pre-
dictive for patient survival times after gemcitabine treatment [30–33].
Conversely, the cellular expression profile of transporters can be altered
by chemotherapeutic drugs [6,18,26,34]. Further, enhanced expression
of ABC transporters seems to be characteristic for cells with cancer stem
cell features [35]. We therefore investigated in this study whether acute
or chronic treatment of pancreatic carcinoma cells with gemcitabine
affects the expression levels of uptake and export transporters involved
in gemcitabine action. Our results demonstrate 1) that gemcitabine
alone or in combination with 5-FU at concentrations relevant for clin-
ical chemotherapy regimens can alter uptake and export transporter ex-
pression in pancreatic cancer cells; 2) that acquired gemcitabine
resistance is paralleled by upregulated or downregulated transporter
expressions, dependent on the specific cell type; and 3) that MRP5
contributes to gemcitabine resistance, as demonstrated with MRP5-
overexpressing and MRP5-silenced cells, that is, overexpression of
MRP5 renders pancreatic cancer cells more resistant to gemcitabine,
whereas silencing of MRP5 expression renders them more sensitive
to gemcitabine.
Materials and Methods
Cells and Drugs
Parental HEK293 cells (HEK; ATCC, Manassas, VA) and estab-
lished human pancreatic carcinoma cell lines (Capan-1, Capan-2,
PANC-1, AsPC-1, BxPC-3, MiaPaCa-2, and PaTu-8902 (PaTu))
[36] were cultured in Dulbeccomodified Eagle medium/HamF-12me-
dium with L-glutamine (PAA, Pasching, Austria) and 10% fetal bovine
serum (Invitrogen, Carlsbad, CA), gentamicin (50 μg/ml), and am-
phothericin B (0.25 μg/ml; PAA); in addition, the culture medium
of MRP5-transfected, MRP5-overexpressing HEK293 cells (HEK/
MRP5 cells; Millennium Pharmaceuticals, Cambridge, MA) contained
geneticin (250 μg/ml). All cells were cultured at 37°C, 5% CO2, and
95% humidity. Gemcitabine was obtained from Eli Lilly (Indianapolis,
IN), 5-FU was from Teva (Kirchzarten, Germany), doxycycline was
from Sigma-Aldrich (St Louis, MO), and tetracycline-free fetal bovine
serum was from Clontech (Mountain View, CA).
Generation of Overexpressing and Knockdown Cell Lines
PANC-1 cells stably overexpressing MRP5 (PANC-1/MRP5 cells)
were obtained by transfection of parental PANC-1 cells with plasmid
containing MRP5 complementary DNA (cDNA) using FuGENE
HD transfection reagent (Roche, Mannheim, Germany) and hygro-
mycin selection as reported [37]. The enhanced expression of MRP5
messenger RNA (mRNA) and protein in these PANC-1/MRP5
clones was checked by quantitative reverse transcription–polymerase
chain reaction (QRT-PCR) and immunoblot, respectively [26]; MRP5
mRNA levels in PANC-1/MRP5 clones exceeded those of parental
PANC-1 cells by more than 300-fold. For the targeted MRP5 knock-
down, PANC-1 cells containing doxycycline-inducible short hairpin
RNA (shRNA) targeting MRP5 mRNA (PANC-1/shMRP5 cells) were
generated using the pSingle-tTS-shRNA vector (Clontech) contain-
ing one of three different oligonucleotides targeting MRP5 mRNA
(target position within the MRP5 mRNA sequence [accession no.
NM_005688]: 158-176, 368-386, or 547-565 bp). Selected PANC-1/
shMRP5 cloneswere kept under geneticin (800μg/ml) andwere cultured
in tetracycline-free medium.MRP5 silencing was checked by QRT-PCR
using PANC-1/shMRP5 clones treated without or with doxycycline
for 3 to 6 days with replenishment of doxycycline every 48 hours.
Drug Treatment of Cells
To establish gemcitabine-resistant cells, cells were adapted to in-
creasing concentrations of gemcitabine (10-160 nM); for this, cells
were exposed to each gemcitabine concentration for at least 14 days
before the drug concentration was doubled in cultures of the surviving
cells. For single short-time drug treatment, cells were treated with gem-
citabine (12 nM) for 72 hours before RNA isolation. Alternatively,
cells were incubated with gemcitabine (20 μM) for 1 hour, then the
medium was replaced with fresh medium containing no gemcitabine,
and RNA was isolated 72 hours later. In experiments comparing the
effects of single or combined treatment of cells, the following schedules
were applied: (a) 5-FU (30 μM) for 24 hours, then fresh drug-free me-
dium; (b) gemcitabine (20 μM) for 1 hour, then fresh drug-free me-
dium; and (c) 5-FU (30 μM) for 24 hours, then gemcitabine (20 μM)
for 1 hour, then fresh drug-freemedium. RNA isolation was performed
at the times indicated in the Results section.
Antibodies
The rat monoclonal antibody M5I-1 against human MRP5 was
from Kamiya (Seattle, WA), the mouse monoclonal antibody
NCL-MRP3 against human MRP3 was from Novocastra (Newcas-
tle, UK), and the mouse monoclonal anti–β-actin antibody (AC-15)
was from Sigma-Aldrich. The secondary antibodies conjugated to
horseradish peroxidase were obtained from Pierce (Rockford, IL) and
Dianova (Hamburg, Germany).
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Immunoblot
Membrane samples were prepared for electrophoresis as reported
[26,38] and subjected to SDS-PAGE on 7.5% polyacrylamide gels.
For one particular cell line, equal amounts of membrane proteins
were loaded per lane. Protein determination was performed using
BSA as standard [39]. After electrophoresis, the separated proteins
were transferred onto polyvinylidene fluoride membranes (Millipore,
Billerica, MA) and immunoblotted using chemiluminescence for de-
tection (SuperSignal West Femto; Pierce). The primary antibodies were
used as follows: anti-MRP5 (M5I-1) and anti-MRP3 (NCL-MRP3),
1:1000; anti–β-actin, 1:10,000. The horseradish peroxidase–conjugated
secondary antibodies were used at a dilution of 1:2000. The half-life
times of MRP5 and MRP3 protein in pancreatic cancer cells and
HEK-MRP5 cells, respectively, were determined by immunoblot using
membranes from cells treated with tunicamycin for 0 to 72 hours as
reported [23]. Quantification and normalization of the immunoblot
signals were performed by densitometric analysis on at least duplicate
immunoblots each from two independent experiments using Alpha
Imager software (Alpha Innotech Corporation, San Leandro, CA).
RT-PCR and QRT-PCR Analyses
Total RNA was isolated from cells using the RNeasy Mini Kit ac-
cording to themanufacturer’s instructions (Qiagen, Hilden, Germany)
and analyzed by RT-PCR as reported [26]. QRT-PCRwas performed in
anMx3000P (Stratagene, Amsterdam, theNetherlands) using ABsolute
QPCR SYBR Green Mix (Abgene, Epsom, UK) in a total volume of
20 μl including 5 μl of the synthesized single-stranded cDNAwith con-
ditions and quality control of amplified products as described [26]. The
relative amounts of target gene mRNA expression compared with the
pancreatic housekeeping geneRPL13A as reference gene were calculated
using the ΔΔC t method. Each QRT-PCR analysis was performed at
least in duplicate technical replicas from at least duplicate biological sam-
ples. The primers specific for RPL13A, MRP1 (ABCC1), MRP3, and
MRP5, their sequences, positions, and length of the respective amplified
fragment were as reported [25,26]. Other specific sense and antisense
primers used for amplification and designed using Primer3 software were
as follows:ENT1 (gene symbol: SLC29A1; accession no.NM_004955),
5′-AGTGGCTCGGAGCTATCAGA-3′ and 5′ GTGCTCGAA-
GACCACAGTCA-3′ (588-bp fragment, bases 918-1505); CNT3
(gene symbol: SLC28A3; accession no. NM_022127), 5′-ATGAATT-
CAGCCCTGTCCTG-3′ and 5′-AAACGTGATGGCAGT-TGATG-
3′ (484-bp fragment, bases 1482-1965);MDR-1 (gene symbol: ABCB1;
accession no. NM_000927), 5′-TGGAGGAGCAAAGAAGAAGAAC-
3′ and 5′-GCAGCCAAAGTTCCCACCAC-3′ (150-bp fragment,
bases 442-591). Specificity of PCR was checked by agarose gel electro-
phoretic analysis of amplicons.
Cytotoxicity Studies
Cells (parental HEK, HEK/MRP5, PANC-1, PANC-1/MRP5, or
PANC-1/shMRP5 cells) were seeded into 96-well plates at a density
of 3000 cells per well. One day later, medium was replaced by fresh
medium containing gemcitabine at the indicated concentration
(range, 0-10 μM). All experimental incubation conditions were per-
formed with at least duplicate biological samples and triplicate tech-
nical samples. Cell viability was determined after 3 days (HEK cells)
or 6 days (PANC-1 cells) of continuous drug treatment using the
WST-1 cell proliferation assay (Roche) and evaluated as described
[26]. For the determination of gemcitabine cytotoxicity in stably
MRP5-silenced PANC-1/shMRP5 cells, cells were treated for 6 days
without or with doxycycline (100 ng/ml), trypsinized, seeded into
96-well plates (3000 cells/well), and exposed to gemcitabine for another
6 days before WST-1 assay; during the whole experiment, doxycycline
was replenished every 48 hours.
Cell Proliferation Rate
Population doubling time was determined during the exponential
growth phase of unsynchronizedmonolayer cultures. Briefly, 2000 cells/
well were seeded onto 96-well plates in growth medium. Cell prolifera-
tion was indirectly assessed using theWST-1 assay as indicated previously,
measuring cell numbers every 24 hours for 3 days. Previous calibration
of the assay had indicated a linear correlation between color develop-
ment and cell numbers in the range of 100 to 20,000 cells.
Results and Discussion
Chemotherapy in human pancreatic carcinoma patients reaches plasma
concentrations of gemcitabine approximating 20 to 90 μM sufficient to
maximize the rate of intracellular gemcitabine triphosphate accumula-
tion [40]. However, the sensitivity of human pancreatic carcinoma cell
lines to the cytotoxic effect of gemcitabine in vitro has been reported to
vary over a wide range of drug concentration, with half-maximal in-
hibitory concentration (IC50) values ranging from few nanomolars to
several micromolars, even for one particular cell line (IC50 values: [a]
gemcitabine continuously on cells for 72 hours: Capan-1 = 11.5 nM,
Capan-2 = 12 nM, AsPC-1 = 14.6 nM, BxPC-3 = 18 nM,MiaPaCa-2 =
36-40 nM, PANC-1 = 50 nM; [b] gemcitabine for 1 hour on cells:
MiaPaCa-2 = 11.0 μM, Capan-1 = 18.1 μM, PANC-1 = 160.5 μM)
[41–44].We hypothesized that treatment of pancreatic cancer cells with
gemcitabine at a cytotoxic concentration might elicit a rescue response
in the surviving cells allowing them to better tolerate gemcitabine. We
incubated several pancreatic carcinoma cell lines (AsPC-1, BxPC-3,
MiaPaCa-2, Capan-1, and PANC-1) with 12 nM gemcitabine, which
represents a drug concentration in the IC50 range for some cell lines.
Such gemcitabine treatment for 3 days did not elicit any significant al-
terations in the mRNA expression levels of exportersMRP1,MRP3, or
MRP5 or the relevant uptake transporter ENT1 in the pancreatic carci-
noma cell lines studied (Figure 1).
In contrast, short-time incubation of pancreatic carcinoma cells
with gemcitabine in a setting more closely resembling the chemother-
apy situation in patients in vivo (20 μMgemcitabine for 1 hour) caused
up-regulation ofmost transporters studied (Figure 2). Interestingly, the
Figure 1. Influence of continuous gemcitabine exposure on trans-
porter expression. Cells were incubated with gemcitabine (12 nM)
for 72 hours before isolation of RNA. The individual expression levels
of the indicated transporters were analyzed by QRT-PCR, normalized
to mRNA expression of RPL13A as pancreatic housekeeping gene,
and shown as x-fold relative to the normalized expression of the re-
spective target gene in untreated control cells (set as 1). Values are
means±SD fromat least duplicate biological and technical samples.
742 Transporters and Gemcitabine in Pancreatic Carcinoma Cells Hagmann et al. Neoplasia Vol. 12, No. 9, 2010
most prominent up-regulation by gemcitabine in this regimen was ob-
served forMRP5 and ENT1 (ca. six- to eight-fold, respectively), both
of which are transporters mediating gemcitabine uptake or export of its
metabolites in pancreatic carcinoma cells [16,17,20]. An analogous ef-
fect on pancreatic ENT1 expression has been demonstrated after 5-FU
treatment [18,45]. In contrast, MRP3 expression either was not af-
fected (AsPC-1, Capan-1, Capan-2, and PANC-1) or was only slightly
upregulated (PaTu, MiaPaCa-2, and BxPC-3 cells; Figure 2). Thus,
most pancreatic cancer cell lines studied reacted to the acute treatment
with a high dose of gemcitabine in a manner that would, by increasing
MRP5 expression, diminish the potential chemotherapeutic action of
the drug by accelerating its elimination from intracellular compart-
ments. Conversely, the concomitantly increased ENT1 expression
would allow the enhanced uptake of nucleosides into these cells.
We next addressed the problem of acquired resistance that pancreatic
tumors are known to develop during chemotherapy with gemcitabine
[46,47]. To this end, wemimicked the clinical situation of drug-induced
resistance by analyzing gemcitabine-resistant pancreatic cancer cell lines
adapted to and maintained in increasing concentrations of the drug.
Compared with the untreated parental cell line, some cells with such
acquired resistance to 160 nM gemcitabine showed increased MRP5
and ENT1 expression (AsPC-1 and MiaPaCa-2; Figure 3), which is in
line with earlier reports on ENT1mRNA levels in different cell lines [6].
In other gemcitabine-resistant cells, we found only MRP5 (PaTu) or
ENT1 (BxPC-3) increased, whereas gemcitabine-resistant Capan-1 cells
demonstrated no change inMRP5 and even a down-regulation ofENT1
expression (Figure 3). Because mRNA expression does not necessarily
correspond to the functional protein level of a gene transcript, we
checked by immunoblot the MRP5 protein expression in parental cells
and in cells adapted to 40 and 160 nM gemcitabine (Figure 4); the half-
life time ofMRP5 andMRP3 protein in pancreatic cancer cells was like-
wise determined to be 35 and 40 hours, respectively. In line with the
mRNA expression data (Figure 3), MRP5 protein levels normalized
to β-actin were slightly upregulated in gemcitabine-resistant Capan-1
cells, were unaffected or downregulated in correspondingly treated
BxPC-3 cells, and were 3- to 3.5-fold upregulated in AsPC-1 and PaTu
cells grown in medium containing 160 nM gemcitabine (Figure 4).
Thus, similar to the observed heterogeneous and cell line–specific altera-
tions in transporter expression of gemcitabine-resistant pancreatic cells
in vitro, individual human pancreatic tumors in vivomay react very dif-
ferently to acute gemcitabine treatment and during development of
gemcitabine resistance with respect to expression of relevant transporters
involved in gemcitabine transport.
Several chemotherapy regimens using gemcitabine together with other
drugs have been developed, some of them combining gemcitabine
with 5-FU and resulting in improved benefit [48–50]. Interestingly,
studies with human pancreatic cancer cells in vitro [18] or in a murine
xenograft model [45] demonstrated an improved therapeutic effect
when 5-FU was administered before gemcitabine. Further, treatment
of cells with 5-FU alters the expression of nucleoside and ABC trans-
porters [18,26,51]. We were thus interested to see how the transporter
profile of pancreatic cancer cells was influenced by the combination of
these chemotherapeutic drugs. Because MRP5 and ENT1 have been
suggested or characterized as export and import transporters of 5-FU
and gemcitabine or their metabolites [14,20,52], we analyzed the ex-
pression of these two transporters. Our QRT-PCR analyses demon-
strated that sequential treatment of three different pancreatic cancer
cell lines by 5-FU followed by gemcitabine elicited a marked additive
up-regulation of both MRP5 and ENT1 within 4 days (Figure 5). As
Figure 2. Alterations in transporter mRNA expression after short-time exposure to gemcitabine. After gemcitabine treatment (20 μM for
1 hour), the indicated pancreatic carcinoma cell lines were grown for 72 hours in drug-free medium before isolation of RNA. Transporter
mRNA expression was analyzed byQRT-PCR as in Figure 1. Values are means± SD from at least duplicate biological and technical samples.
Figure 3. MRP5 and ENT1 mRNA expression in cells with acquired
gemcitabine resistance. RNA was extracted from untreated control
cells (open bars) or from cells stepwise adapted to and cultured for
at least 14days inmediumcontaining160nMgemcitabine (filledbars).
NormalizedmRNAexpression levels forMRP5 (upper panel) andENT1
(lower panel) were analyzed by QRT-PCR as in Figure 1. Values are
means from at least duplicate biological and technical samples.
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shown forMRP5 in PANC-1 cells, the increase in transporter expression
was noticeable 2 days after start of drug treatment and was maximal
within 4 days (Figure 6). Whereas single drug treatment with 5-FU
or gemcitabine alone also elicited the enhanced expression of MRP5
and ENT1 (Figure 5), this up-regulation was highest in all cases after
combined drug administration and was most prominent in Capan-1
and PANC-1 cells: in Capan-1 cells, the drug combination caused a
32.8 ± 10.2-fold (mean ± SEM) increase of MRP5 and a 52.4 ± 11.7-
fold rise in ENT1 expression compared with control cells (Figure 5); in-
terestingly, the expression of the nucleoside transporter CNT3 increased
more than 100-fold in 5-FU/gemcitabine–treated Capan-1 cells, whereas
concomitantlyMDR-1 was elevated only about 5-fold (data not shown).
In PANC-1 cells, MRP5 was elevated 13.7 ± 4.3-fold, and ENT1 was
elevated 17.4 ± 8.7-fold after 5-FU/gemcitabine treatment (Figure 5).
MiaPaCa-2 cells also reacted correspondingly albeit weaker to this drug
regimen, withMRP5 expression rising 5.2 ± 0.1-fold and ENT1 by 1.6 ±
0.3-fold compared with untreated control cells (Figure 5). We also
checked whether the observed enhanced transporter mRNA expression
after 5-FU and gemcitabine resulted in elevated cellular protein levels
of the drug transporters. As demonstrated by MRP5 immunoblot, the
up-regulation of MRP5 mRNA expression was paralleled by a corre-
spondingly enhanced expression ofMRP5 protein, which again was most
prominent in PANC-1 and Capan-1 cells after single or combined drug
treatment (Figure 7). Thus, our data indicate that the cytotoxic action of
gemcitabine, 5-FU, and a combination of both drugs elicits a strongly
increased expression of the export pump MRP5, which diminishes the
chemotherapeutic efficiency of these drugs by allowing a faster drug
detoxification through enhanced excretion by MRP5 from pancreatic
carcinoma cells. However, the concomitant up-regulation of the up-
take transportersCNT3 and ENT1may support cell survival by improv-
ing their import capacity for physiologic nucleobases and nucleosides
but can also improve the bioavailability and thus the chemotherapeutic
efficacy of gemcitabine bymodulation the expression of its main uptake
transporter ENT1 [53]. This interpretation is in line with an earlier
study that had demonstrated superior chemotherapeutic benefit by
using 5-FU administration followed by gemcitabine treatment in mice
in vivo [45]. Further studies will investigate the potential signaling path-
ways involved in this drug-evoked up-regulation of transporter expres-
sion such as altered transcription factor levels or promoter induction
through epigenetic mechanisms such as DNA demethylation or histone
deacetylation [54,55].
Because drug export through MRP transporters has been demon-
strated to contribute to cellular resistance against various chemothera-
peutic compounds [26–29,56–58], we tested the suggested ability of
MRP5 to affect chemoresistance against gemcitabine [20,29,59]. To
this end, we compared the gemcitabine sensitivity of parental HEK
cells with transfected HEK cells stably overexpressing human MRP5
(HEK/MRP5 cells). The endogenous MRP5 protein expression in
parental HEK cells is low, whereas HEK/MRP5 cells contain at least
10-fold moreMRP5 protein, as estimated from the immunoblot signal.
QRT-PCR analysis indicated that MRP5 mRNA expression in HEK/
MRP5 cells is increased approximately 410 ± 49-fold (mean ± SD) com-
pared with that in parental HEK cells (control), whereas the expressions
of ENT1 andCNT3 are almost identical in these two cell lines (ENT1 =
0.9- andCNT3 = 1.4-fold control). Our cytotoxicity studies with these
cells showed that MRP5-overexpressing HEK/MRP5 cells indeed
showed increased resistance against gemcitabine (IC50 = 45 nM; Fig-
ure 8, upper panel ), compared with parental HEK cells (IC50 = 15 nM;
Figure 8, upper panel ). Such altered gemcitabine resistance due to
Figure 4.MRP5protein expression in cellswith acquiredgemcitabine
resistance. Indicated pancreatic cancer cell lines were adapted to
increasing concentrations of gemcitabine as described in theMate-
rials and Methods section. After culturing the cells at the indicated
gemcitabine concentration for at least 14 days,membrane fractions
were isolated from these cells and subjected to immunoblot analy-
sis for MRP5 and β-actin. MRP5 protein expression was normalized
to the corresponding immunoblot signal for β-actin on the same
PVDF membrane. Representative immunoblot analysis each per-
formed twice on samples from two independent experiments.
Figure 5. Individual and combined effects of 5-FU and gemcitabine on transporter expression. Treatment of indicated pancreatic cancer
cells was as follows: FU: 30 μM 5-FU, 24 hours (gray bars); G: 20 μM gemcitabine, 1 hour (hatched bars); FU + G: 30 μM 5-FU, 24 hours,
followed by 20 μMgemcitabine, 1 hour (black bars). RNA from treated or untreated control cells (Co; empty bars) was extracted 4 days after
start of 5-FU or 3 days after gemcitabine treatment, respectively. Expression of MRP5 (left panel) and ENT1 mRNA (right panel) was
analyzed and normalized by QRT-PCR as in Figure 1. Data represent mean values from three independent experiments, each with treat-
ment conditions performed in duplicate, and all technical samples are analyzed at least in duplicate.
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different MRP5 expression levels was also observed in PANC-1 cells
overexpressing MRP5 (PANC-1/MRP5 cells; Figure 8, lower panel ).
Compared with parental PANC-1 cells (IC50 = 9 nM), the IC50 value
for gemcitabine in PANC-1/MRP5 cells amounts to ca. 200 nM (Fig-
ure 8). Because the cytotoxic action of gemcitabine depends on cell pro-
liferation, we determined whether the gemcitabine-resistant PANC-1/
MRP5 cells differ in their growth rate from parental PANC-1 cells.
However, no significant difference in the population doubling time be-
tween PANC-1 and PANC-1/MRP5 cells was observed when cells were
grown as unsynchronized monolayer cultures (population doubling
time: 40 and 38 hours for PANC-1 and PANC-1/MRP5 cells, respec-
tively). Thus, the marked difference in gemcitabine sensitivity between
PANC-1 and PANC-1/MRP5 cells is not due to a corresponding differ-
ence in cell proliferation rates.
Next, we investigated the role ofMRP5 in gemcitabine resistance by
silencing this transporter in PANC-1 cells by specific RNA interfer-
ence. We used three different shRNA oligonucleotides, each targeting
specific regions of the MRP5 mRNA sequence. Judging from the
QRT-PCR analyses, we achieved at best an 80% knockdown of MRP5
mRNA in stably transfected PANC-1/shMRP5 cells after doxycycline-
induced silencing. Such MRP5-silenced, doxycycline-treated PANC-1/
shMRP5 cells indeed showed an increased chemosensitivity toward
gemcitabine (IC50 = 4 nM; Figure 9) compared with their untreated
counterpart (PANC-1/shMRP5 cells: IC50 = 20 nM). Thus, our experi-
mental data analyzing gemcitabine sensitivity in cells with either increased
Figure 6. Time course ofMRP5 induction by 5-FU and gemcitabine
in PANC-1 cells. Cells were exposed to 30 μM 5-FU for 1 day, fol-
lowed by treatment with 20 μM gemcitabine for 1 hour. RNA was
extracted from cells before treatment or at the indicated time points
after start of drug treatment. Expression ofMRP5mRNAwas analyzed
and normalized by QRT-PCR as in Figure 1. Insert shows agarose gel
electrophoretic analyses and ethidium bromide staining of amplicons
forMRP5 and RPL13A after RT-PCR.
Figure 7. MRP5 protein expression after 5-FU and gemcitabine
treatment in pancreatic cancer cells. Immunoblot detection of
MRP5 and β-actin was performed with membranes from untreated
control cells (Co) or from cells treated with 5-FU (FU), gemcitabine
(G), or with 5-FU followed by gemcitabine (FU + G) as described in
Figure 5. Representative immunoblot analysis each performed
twice on samples from two independent experiments.
Figure 8. MRP5 and gemcitabine chemosensitivity of HEK and
PANC-1 cells. Parental HEK cells (open triangles, upper panel) and
MRP5-overexpressing HEK/MRP5 cells (filled triangles, upper panel)
or PANC-1 cells (open circles, lower panel) and MRP5-overexpress-
ing PANC-1/MRP5 cells (filled circles, lower panel) were subjected to
gemcitabine (HEK: 0-100 nM for 4 days; PANC-1: 0-10 μMfor 6 days)
before cytotoxicity assay usingWST-1. Values aremeans from two in-
dependent experiments performed with each condition in triplicate;
bars indicate SD.
Figure 9. Gemcitabine chemosensitivity inMRP5-silenced PANC-1/
shMRP5 cells. PANC-1 cells containing doxycycline-inducible
shRNA targetingMRP5mRNA (PANC-1/shMRP5 cells)were treated
with doxycycline (100 ng/ml; open circles) or vehicle (filled circles)
for 6 days and exposed to indicated gemcitabine concentrations for
another 6 days before determination of cell viability usingWST-1 as-
say. Values are means from triplicate samples; bars indicate SD.
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or diminished expression of MRP5 suggest that this ABC transporter
contributes to gemcitabine resistance in pancreatic cancer cells. This is
in line with data from gemcitabine-sensitive lung cancer cells showing
a correlation between MRP5 expression and gemcitabine action [29].
In conclusion, our studies showed 1) that chemotherapeutic treat-
ment of pancreatic cancer cells with gemcitabine alone or in combina-
tion with 5-FU at concentrations relevant for chemotherapy regimens
can change the expression levels of transporters that are involved in
gemcitabine uptake or elimination; 2) that acquired gemcitabine resis-
tance is paralleled by upregulated or downregulated transporter expres-
sions, dependent on the specific cell type; and 3) that the multidrug
resistance protein MRP5 represents an additional and novel entity
among the various cellular factors influencing gemcitabine resistance
of pancreatic cancer. Thus, the efficacy of future chemotherapeutic
regimens using gemcitabine and/or 5-FUmay benefit from taking into
account the observed alterations of relevant transporter expression lev-
els induced by the chemotherapeutic drugs. Particularly, the develop-
ment and use of specific inhibitors of MRP5 may be an important aim
for this purpose. This may hold true especially for pancreatic tumor
cells with known gemcitabine resistance, where, for example, inhibition
of nuclear factor κB was shown to be ineffective [60]. In addition, the
observed heterogeneous response of different human pancreatic cancer
cells regarding their MRP5 transporter expression after gemcitabine
treatment may reflect the heterogeneous response pattern in vivo and
would argue for an individualized screening test before chemotherapy
in patients to improve the efficacy of the intended treatment.
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